The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study
Open accessAbstract
We studied the clinical and immunological effects of Rituximab (anti-CD20) therapy in patients with lupus nephritis. In an open clinical trial, 22 patients with active systemic lupus erythematosis and renal involvement (mainly class III and IV according to the WHO classification) that was refractory to conventional therapy were studied. In all these patients, Rituximab (0.5 to 1.0 g at days 1 and 15) was added to the immunosuppressive therapy and its therapeutic effect was evaluated. In addition, the levels and function of regulatory T lymphocytes and the apoptosis of immune cells were assessed. We found a significant reduction in disease activity (p < 0.05, MEX-SLEDAI index), and proteinuria (p < 0.05) at days 60 and 90 of Rituximab therapy. Although most patients showed improvement in creatinine clearance and erythrocyturia, no significant changes in these parameters were detected. In most patients (20/22), B cell depletion was observed, but no clear-cut effect of Rituximab on complement levels or auto-antibody titers was detected (p > 0.05 in all cases). One patient died at day 70 with invasive histoplasmosis. No important adverse effects of Rituximab therapy were registered in other patients. A significant enhancement in the levels of different CD4+ regulatory cells (T REG, Th3, Tr1), but not CD8+ Ts lymphocytes, was observed at day 30. This increase was sustained for T REG cells at day 90, and accompanied by an improvement in their regulatory function. In addition, we observed an unexpected increase in the apoptosis of T cells at day 30. Interestingly, the enhancement in the suppressive function of T REG cells was not observed in the two patients that showed the poorest clinical response to Rituximab. We conclude that the data obtained in this open clinical trial suggest that Rituximab is a promising candidate for randomized controlled trials in patients with lupus nephritis refractory to the conventional immunosuppressive therapy. The effects of Rituximab on regulatory cells and apoptosis of T lymphocytes are interesting and its possible role in the putative effect of this biological agent in systemic lupus erythematosis deserves additional studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Park, J.-H., Adoro, S., Guinter, T., Erman, B., Alag, A. S., Catalfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
(2016) · Diagnostic Imaging: Brain · doi:10.1016/b978-0-323-37754-6.50094-4 · Cited by 3,990
Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis
Viglietta, V., Baecher-Allan, C., Weiner, H. L., & Hafler, D. A. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031579 · Cited by 1,856
Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα Therapy
Ehrenstein, M. R., Evans, J. G., Singh, A., Moore, S., Warnes, G., Isenberg, D. A., & Mauri, C. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040165 · Cited by 1,252
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL
Boise, L. H., Minn, A. J., Noel, P. J., June, C. H., Accavitti, M. A., Lindsten, T., & Thompson, C. B. (1995) · Immunity · doi:10.1016/1074-7613(95)90161-2 · Cited by 1,210
Regulatory T cells in the control of immune pathology
Maloy, K. J., & Powrie, F. (2001) · Nature Immunology · doi:10.1038/ni0901-816 · Cited by 1,175
Roncarolo, M. G., Bacchetta, R., Bordignon, C., Narula, S., & Levings, M. K. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820105.x · Cited by 814
Regulatory T cells and mechanisms of immune system control
O'Garra, A., & Vieira, P. (2004) · Nature Medicine · doi:10.1038/nm0804-801 · Cited by 810
Looney, R. J., Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Arend, L. J., Sloand, J. A., Rosenblatt, J., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20430 · Cited by 776
Renal Disease. Classification and Atlas of Glomerular Diseases.
(1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-5-801_2 · Cited by 672
Disturbed Peripheral B Lymphocyte Homeostasis in Systemic Lupus Erythematosus
Odendahl, M., Jacobi, A., Hansen, A., Feist, E., Hiepe, F., Burmester, G. R., Lipsky, P. E., Radbruch, A., & Dörner, T. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5970 · Cited by 642
An open study of B lymphocyte depletion in systemic lupus erythematosus
Leandro, M. J., Edwards, J. C., Cambridge, G., Ehrenstein, M. R., & Isenberg, D. A. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10541 · Cited by 576
Llorente, L., Zou, W., Levy, Y., Richaud-Patin, Y., Wijdenes, J., Alcocer-Varela, J., Morel-Fourrier, B., Brouet, J. C., Alarcon-Segovia, D., Galanaud, P., et al. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.181.3.839 · Cited by 541
Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus
Anolik, J. H., Barnard, J., Cappione, A., Pugh‐Bernard, A. E., Felgar, R. E., Looney, R. J., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20592 · Cited by 456
Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Sanz, I., Rosenblatt, J., & Looney, R. J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10764 · Cited by 429
Sfikakis, P. P., Boletis, J., Lionaki, S., Vigklis, V., Fragiadaki, K., Iniotaki, A. G., & Moutsopoulos, H. Μ. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20858 · Cited by 410
Quantification of regulatory T cells in patients with systemic lupus erythematosus
Crispin, J. C., Martı́nez, A., & Alcocer-Varela, J. (2003) · Journal of Autoimmunity · doi:10.1016/s0896-8411(03)00121-5 · Cited by 408
Mills, J. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406303302608 · Cited by 407
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
Gottenberg, J.-E., Guillevin, L., Lambotte, O., Combe, B., Allanore, Y., Cantagrel, A., Larroche, C., Soubrier, M., Bouillet, L., Dougados, M., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.029694 · Cited by 401
Rituximab: Mechanism of action and resistance
Maloney, D. G., Smith, B., & Rose, A. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30156 · Cited by 375
Leandro, M. J., Cambridge, G., Edwards, J. C., Ehrenstein, M. R., & Isenberg, D. A. (2005) · Rheumatology · doi:10.1093/rheumatology/kei080 · Cited by 364
Cao, D., Vollenhoven, R. V., Klareskog, L., Trollmo, C., & Malmström, V. (2004) · Arthritis Res Ther · doi:10.1186/ar1192 · Cited by 359
Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells
Tone, M., Tone, Y., Adams, E., Yates, S. F., Frewin, M. R., Cobbold, S. P., & Waldmann, H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2334901100 · Cited by 345
CD25+ cell depletion hastens the onset of severe disease in collagen‐induced arthritis
Morgan, M. E., Sutmuller, R. P. M., Witteveen, H. J., van Duivenvoorde, L. M., Zanelli, E., Melief, C. J. M., Snijders, A., Offringa, R., de Vries, R. R. P., & Toes, R. E. M. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11063 · Cited by 305
Mechanism of action of rituximab
Cerny, T., Borisch, B., Introna, M., Johnson, P., & Rose, A. L. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200211002-00002 · Cited by 287
Decreased CD4+CD25+ T Cells in Peripheral Blood of Patients with Systemic Lupus Erythematosus
Liu, M. ‐., Wang, C. ‐., Fung, L. ‐., & Wu, C. ‐. (2004) · Scandinavian Journal of Immunology · doi:10.1111/j.0300-9475.2004.01370.x · Cited by 282
The central and multiple roles of B cells in lupus pathogenesis
Chan, O. T. M., Madaio, M. R., Shlomchik, M. J., Chan, O. I. M., Madaio, M. P., & Shlomchik, M. J. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01310.x · Cited by 281
Specific suppression of T helper alloreactivity by allo-MHC class I- restricted CD8+CD28- T cells
Liu, Z. (1998) · International Immunology · doi:10.1093/intimm/10.6.775 · Cited by 267
The B cell surface molecule B1 is functionally linked with B cell activation and differentiation.
Tedder, T. F., Boyd, A. W., Freedman, A. S., Nadler, L. M., & Schlossman, S. F. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.2.973 · Cited by 226
T-regulatory 1 cells: A novel subset of CD4+ T cells with immunoregulatory properties
Levings, M. K., & Roncarolo, M.-G. (2000) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2000.106635 · Cited by 177
Golay, J. T., Clark, E. A., & Beverley, P. C. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.6.3795 · Cited by 175
Impairment of CD8+ T Suppressor Cell Function in Patients with Active Systemic Lupus Erythematosus
Filaci, G., Bacilieri, S., Fravega, M., Monetti, M., Contini, P., Ghio, M., Setti, M., Puppo, F., & Indiveri, F. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.10.6452 · Cited by 165
B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus
Marks, S. D., Patey, S., Brogan, P. A., Hasson, N., Pilkington, C., Woo, P. M., & Tullus, K. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21351 · Cited by 144
Abnormal T cell signal transduction in systemic lupus erythematosus
Kammer, G. M., Perl, A., Richardson, B. C., & Tsokos, G. C. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10192 · Cited by 139
Wohlfert, E. A., Gorelik, L., Mittler, R. S., Flavell, R. A., & Clark, R. B. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1316 · Cited by 138
Monk, C. R., Spachidou, M. P., Rovis, F., Leung, E., Botto, M., Lechler, R. I., & Garden, O. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20976 · Cited by 129
T- and B-Cell Abnormalities in Systemic Lupus Erythematosus
Nagy, G., Koncz, Á., & Perl, A. (2005) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v25.i2.30 · Cited by 123
Regulatory/suppressor T cells in health and disease
Shevach, E. M. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20500 · Cited by 109
Immune cells and cytokines in systemic lupus erythematosus: an update
Kyttaris, V. C., Juang, Y.-T., & Tsokos, G. C. (2005) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000170479.01451.ab · Cited by 94
van Vollenhoven, R., Gunnarsson, I., Henriksson, E. W., Sundelin, B., Österborg, A., Sh, J., & Klareskog, L. (2004) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740410010227 · Cited by 93
Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy
Weide, R., Heymanns, J., Pandorf, A., & Köppler, H. (2003) · Lupus · doi:10.1191/0961203303lu449cr · Cited by 85
Protein Kinase C-θ Mediates a Selective T Cell Survival Signal Via Phosphorylation of BAD
Villalba, M., Bushway, P., & Altman, A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.10.5955 · Cited by 83
B cell depletion in autoimmune disease.
Gorman, C., Leandro, M. J., & Isenberg, D. A. (2003) · Arthritis Research · doi:10.1186/ar1007 · Cited by 57
Anti‐CD20 therapy in systemic lupus erythematosus: A step closer to the clinic
Silverman, G. J. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20857 · Cited by 39
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Rovin, B. H., Furie, R., Latinis, K., Looney, R. J., Fervenza, F. C., Sanchez‐Guerrero, J., Maciuca, R., Zhang, D., Garg, J. P., Brunetta, P., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34359 · Cited by 1,461
D'Cruz, D. P., Khamashta, M. A., & Hughes, G. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60279-7 · Cited by 992
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Effector and regulatory B cells: modulators of CD4+ T cell immunity
Lund, F. E., & Randall, T. D. (2010) · Nature Reviews Immunology · doi:10.1038/nri2729 · Cited by 638
Metadata
- Authors
- Vigna-Perez, M., Hernández-Castro, B., Paredes-Saharopulos, O., Portales-Pérez, D., Baranda, L., Abud-Mendoza, C., & González-Amaro, R.
- Venue
- Arthritis Research & Therapy
- Published
- 2006-05-05
- Volume
- 8
- Issue
- 3
- Pages
- R83-R83
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W1938487222
- Cited by
- 303
- References
- 45
- FWCI
- 20.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.